ACOG
NASD Alpha Cognition Inc$8.84 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.84, $0.25 below the day’s high of $9.09
- YTD change
- +36.00%
- vs 20-day SMA
- +0.06%
- vs 200-day SMA
- +26.76%
Price ranges
Price & Performance
+2.87 (+48.07%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 23.4% away from all-time highs of $11.54
- ACOG is up 36% since the beginning of the year
- ACOG is up 26% over the past 12 months
- ACOG is down 1% over the past 1 month
- 1% of all ACOG investors are betting against ACOG
ACOG reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +25.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -2.86%
- vs 8-day SMA
- -1.85%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062INâ€) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
